Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer - Supplementary Material

Supplemental Table 1: PICOS criteria to identify and select trials for the SRSupplemental Table 2. Search strategy for EMBASE 1974 to 2022 April 20Supplemental Table 3. Search strategy for Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to April 19, 2022Supplemental Table 4. Search strategy for EBM Reviews - Cochrane Central Register of Controlled Trials March 2022Supplemental Table 5. List of included trials Supplemental Table 6. Risk of bias assessment for included trialsSupplemental Table 7. Treatment characteristics of included trialsSupplemental Table 8. Patient characteristics in included trialsSupplemental Table 9. Survival outcome definitions in included trialsSupplemental Table 10. Reported overall and progression-free survival hazard ratiosSupplemental Table 11. Safety outcomes reported by included trialsSupplemental Table 12. Data sources and populations for network meta-analysisSupplemental Table 13. Constant HRs for OS and PFS used in the network meta-analysisSupplemental Table 14. Constant HRs for OS used in the sensitivity network meta-analysis excluding E2100 and MERiDiAN trialsSupplemental Table 15. Sensitivity network meta-analysis excluding E2100 and MERiDiAN trials